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CTL recognise peptides derived from protein antigens bound to MHC class I 
molecules. Proteasomes probably participate in the generation of these peptide epitopes. 
We investigated the role of proteasomes in presentation of endogenously-synthesised short 
viral proteins. To this end, we employed proteasome and cysteine protease inhibitors, and 
two closely related recombinant vaccinia viruses that code for 17- and 19-amino-acid-long 
products encompassing murine CMV 9pp89 epitope. Presentation of both minigene products 
required processing to shorter peptides and was independent of ubiquitination. Proteasomes 
were necessary for processing the 17mer product, and cysteine proteases were not 
required. In contrast, the 19mer product could be processed in parallel either by 
proteasomes or by cysteine proteases independently. These results highlight the diversity of 
alternative processing pathways even for short peptidic antigens, provide evidence for the 
involvement of cysteine proteases in MHC class I presentation, and show that cleavage by 






Recognition of infected cells by CTL requires prior proteolytic processing of viral 
proteins in the cytosol. This degradation generates peptides that are translocated to the 
endoplasmic reticulum (ER)3 lumen by TAP, and then assemble withE2-microglobulin and 
MHC class I heavy chain (1,2). 
 Some evidences suggest that proteasomes are involved in antigen processing. MHC 
expression and antigen presentation is closely related to expression and activity of 
proteasome subunit LMP7 (3). Also, synthetic peptides are degraded in vitro by purified 20S 
proteasomes to 5-15-amino-acid-long fragments. In some cases, low amounts of 
immunodominant nonamers are found among these products (4,5). In infected cells, it is 
thus assumed that proteins undergo proteolytic processing by proteasomes. However, it is 
not so clear what would be the fate of intermediate -or final- products of this reaction, that is, 
longer peptides with more amino acids than the optimal epitope sequence. One possibility is 
that they are cleaved to final optimal size by proteasomes (4). Alternatively, they may be 
transported by TAP (6), and still be presented by MHC, albeit with lower affinity (7), or be 
trimmed in the ER to optimal size and then efficiently bind to MHC (1,2,8,9). 
 Lactacystin has been characterised recently as a potent inhibitor of the three distinct 
peptidase activities of the multicatalytic complex proteasome. This inhibition seems to be 
proteasome-specific because none of five other proteases tested were inhibited (10,11). This 
reagent appears to modify covalently the conserved N-terminal threonine of mammalian 
proteasome subunit MB1 (10). Z-L3VS is another covalent and irreversible inhibitor of all 
three activities of the proteasome (12), and has also been reported as an extremely potent 
and specific cysteine protease inhibitor (13). E-64 is a classical and effective irreversible 
inhibitor of cysteine proteases (14,15). 
 In the immune response against murine CMV, the nonapeptide 168YPHFMPTNL176 




H-2Ld molecule in BALB/c mice (16-21). In addition, insertion of the 9pp89 sequence into the 
hepatitis B virus e-protein (HBe) (22) as well as construction of minigenes coding for 
peptides 17- and 19-amino-acids-long encompassing this epitope (5) revealed that local 
flanking amino acid residues influence antigen processing and presentation. 
In this work, we studied antigen processing from recombinant vaccinia viruses (rVVs) 
encoding the two minigenes encompassing murine CMV pp89 immunodominant epitope. By 
using the protease inhibitors, we defined the role of proteasomes in endogenous antigen 
processing of short antigens, as well as the differential processing of these two closely 




Materials and Methods 
 
Mice. BALB/c mice (H-2d haplotype) were bred in our colony. 
Cell lines. All cell lines were cultured in IMDM supplemented with 10% FCS and 1% 
2-ME. Cells transfected with Ld were used : L/Ld cells were obtained from Dr. U. H. 
Koszinowski (17) and T2/Ld cells were provided by Dr. Peter Creswell (23).  
Recombinant vaccinia viruses. The rVVs encoding the minigenes, rVV-m17 and rVV-
m19, have been described previously (5). Two other recombinants were used as controls, 
those encoding hepatitis B virus e-protein, rVV-HBe (24), and murine CMV 9pp89 
immunodominant epitope biterminally flanked by alanines and inserted into the amino 
terminus of HBe, rVV-HBe/N/A59pp89A5 (22).  
T cell lines and cytolytic assays. Polyclonal pp89-monospecific CTL were generated 
by immunisation of mice with murine CMV as described previously (17,25). Splenocytes 
thereof were restimulated in vitro with mitomycin C-treated spleen cells pulsed with 10-6 M 
9pp89 peptide, and cultured in a-MEM supplemented with 10% FCS, 4x10-8 M 9pp89 and 
1% 2-ME. These cells were used as effector cells in standard 4-6 hr cytolytic assays (17). 
Transfected cells were used as target cells after overnight infection with rVVs as described 
(17). The data are mean values of at least two experiments. Recombinant human interleukin 
2 for the long-term propagation of pp89-specific CTL lines was generously provided by 
Hoffmann-LaRoche. 
Reagents. Lactacystin and Z-L3VS were gifts from Drs. S. Omura and H. Ploegh, 
respectively. Cysteine proteases inhibitor L-trans-epoxysuccinyl-leucylamido(4-
guanidio)butane (E-64) was from Boehringer Mannheim, Germany.  9pp89 peptide was 
synthesised in an Applied Biosystems peptide synthesiser model 431A, purified, and found 




Results and Discussion 
To determine the involvement of proteasomes in antigen processing, two related 
minigenes encoded by rVVs were used (5). One minigene (m17) codes for a 17mer peptide 
representing the immunodominant murine CMV 9pp89 epitope and the local flanking amino 
acids of HBe carrier protein (MDIGYPHFMPTNLGDPY). The second minigene (m19) codes 
for a 19mer peptide (MDIGAYPHFMPTNLAGDPY) that differs from the previous minigene 
by a biterminal alanine spacer between 9pp89 core and HBe flanking residues. Antigen 
presentation from these minigenes has been previously described and found to be of 
different efficacy (5). Direct detection of the minigene products was not feasible even by 
using SDS-PAGE tricine gels for resolution of low-molecular-weight peptides and high 
sensitivity Western blotting (data not shown), that nevertheless resolved and detected the 
equivalent synthetic peptides. This presumably indicates that low amounts of both minigene 
products were present in infected cells. Fig. 1 shows the recognition by pp89-specific CTL of 
cells expressing each minigene product in comparison with the full-size HBe protein 
containing 9pp89 epitope, in rVV-HBe/N/A59pp89A5. As shown in this figure, presentation of 
both 17- and 19mer products was TAP-dependent. 
Lactacystin has been described as the first proteasome-specific inhibitor (10,11). L/Ld 
cells were treated with lactacystin and infected with rVVs encoding either minigene. Target 
cells infected with rVV-m17 and treated with lactacystin failed to present 9pp89 epitope to 
specific CTL as shown in Fig. 2. The same was true for rVV-HBe/N/A59pp89A5 (data not 
shown). By contrast, in the same experiment, lactacystin had no effect on the specific 
recognition of target cells infected with rVV-m19 (Fig. 2). Lactacystin concentrations up to 
100 PM produced the same selective inhibition (data not shown). Thus, although 
proteasomes may be involved in antigen processing of the 19-aa-long product, these data 
suggest that  the lactacystin-inhibitable proteasome activity is not absolutely required. On the 
other hand, this selective block in antigen presentation of rVV-m17 directly implied 




Previous characterisation of products of in vitro degradation by 20S proteasomes of 
the 17mer synthetic peptide showed partial cleavage of this peptide to yield a 13mer peptide, 
while the 9mer core was not detected (5). We extend this observations to demonstrate the in 
vivo requirement of proteasomes for processing the 17mer minigene product. Controversial 
data have suggested a role for the ubiquitin-activating enzyme E1 in antigen presentation by 
MHC class I molecules (26,27).  Whereas one would expect that full-length proteins such as 
HBe/N/A59pp89A5 might be susceptible to ubiquitin-dependent proteasome-mediated 
degradation, 17mer and 19mer products lack lysine residues important for ubiquitination 
(28). Thus, our data show in vivo ubiquitin-independent processing of a 17mer peptide by 
proteasomes. A recent study (29) demonstrates that lactacystin inhibits the specific 
presentation of epitopes to specific CTL only when these are included in a complete protein 
but not when they are expressed as optimal antigenic size nonamers from minigenes 
encoded in rVVs. The latter are directly translocated by TAP to the ER lumen and may bind 
to MHC class I molecules without processing. Our data show that the presentation of one 
minigene product was blocked by lactacystin and thus proteasome-dependent degradation is 
implied in the cytosolic generation of the corresponding epitope. Therefore, when a few 
amino acids flanked the minimal epitope, proteasome processing and TAP-dependent 
translocation were necessary for short peptides. 
In addition, the 19mer minigene product was presented independently of proteasome 
activity. In order to study whether other proteases were involved in its processing, similar 
experiments were carried out with another recently described inhibitor of both cysteine 
proteases and proteasomes, Z-L3VS (12,13). As opposed to the selectivity observed with 
lactacystin, recognition of both rVV-m17 and rVV-m19 was abolished by Z-L3VS (Fig. 3). 
Both constructs behaved also equally at higher and lower concentrations tested, 10-100 PM 
(data not shown). None of the concentrations used resulted in any inhibition of antigen 
synthesis and accumulation, as controlled with rVV-HBe/N/A59pp89A5 (data not shown). 




including calpain, cathepsin B, and papain (10), the inhibitory effect of Z-L3VS, in contrast to 
that of lactacystin, demonstrated specific inhibition of a cysteine peptidase activity involved 
in processing of the 19mer minigene product. Multiple studies have defined different cysteine 
proteases in distinct compartments related to the MHC class I presentation pathway (ER 
lumen, cis-Golgi, trans-Golgi network, and plasma membrane) (30-36) and in the cytosol 
(37). A recent study (38) showed that in vitro processing of OVA with aspartic proteases 
generates the MHC class II-restricted OVA322-336 epitope. In contrast, digestion of OVA with 
cysteine proteases destroyed this epitope. The authors suggested that mechanisms must 
exist for the protection of epitopes from destructive proteolysis in different compartments. 
Notably, the sequence of 9pp89 epitope YPHFMPTNL presents the N-terminal X-Pro 
sequence described as a structural protection motif against most frequent proteolytic 
degradation (39). Our data, in contrast to the cited study, show that cysteine proteases 
generated a class I-restricted epitope. 
The  proteasome-independent and cysteine-protease-dependent presentation of the 
19mer minigene product can be explained by two hypotheses: first, cysteine proteases may 
be necessary to process the 19mer minigene product. As an alternative, both these 
proteases and proteasomes may be on their own sufficient. To discriminate between these 
possibilities, the effect on minigene antigen presentation of the cysteine-protease-specific E-
64 reagent was tested. Presentation of both rVV-m17 and rVV-m19 was unaffected by E-64 
(Fig. 4). Both constructs were equally resistant to inhibition in the range of 1-500 PM (data 
not shown). As opposed to the lack of effect on rVV-m19 recognition by CTL when each 
inhibitor was used alone, combination of E-64 and lactacystin blocked presentation of rVV-
m19 (Fig. 5), confirming the results with Z-L3VS. It is important to recall that combined 
inhibition of proteasomes and cysteine proteases did not result in any inhibition of antigen 
synthesis and accumulation, as controlled with Z-L3VS. These data confirm that the 17mer 
product was processed by proteasomes and did not require cysteine proteases.  




processed by cysteine proteases as well as by proteasomes. Digestion of 19mer synthetic 
peptide with 20S proteasomes in vitro yields as main cleavage product a 14mer and 
secondly the 9pp89 epitope core (5). Thus, our results confirm suggestions from in vitro 
experiments that proteasomes would be sufficient alone for processing the 19mer, and 
uncover an additional pathway operating in vivo. Because neither proteasomes nor cysteine 
proteases were absolutely required, our data showed that both cleavage pathways were 
independently processing the 19mer product for presentation by Ld. Thus, in the presence of 
lactacystin, cysteine proteases would process the peptide, whereas in the presence of E-64 
proteasomes would be responsible for it, yielding in both cases targets recognised by 
specific CTL. Only when both activities were blocked by Z-L3VS or by the combination of 
lactacystin and E-64, no presentation was detected, indicating that the proteasome and the 
cysteine protease pathways are the only two involved in processing the 19mer. 
Processing of both minigene products by proteasomes in the cytosol would be 
followed by transport to the ER by TAP and binding and presentation by MHC class I 
molecules. The 19mer alternative cysteine protease processing pathway may proceed in the 
cytosol, in the secretory pathway, or in both, since this type of proteases have been 
described in several cellular compartments (30-37). In the first possibility, cytosolic cysteine 
proteases may process the 19mer minigene product prior to transport by TAP. As an 
alternative, the full-length 19mer would be translocated to the ER lumen by TAP, and 
cysteine proteases in the ER or in the secretory pathway would be responsible for its 
processing. Selective TAP-dependent transport to ER lumen of peptides longer than 
nonamers has been described (6). Also, limited antigenic processing in the ER has been 
described for both full-length proteins and short peptides (1,2,8,9). In the two pathways 
described in this report, cytosolic or ER trimming by proteases other than proteasomes and 
cysteine proteases is not excluded.  
In summary, this study demonstrated selective involvement of proteasomes and 




provided evidence for the involvement of cysteine proteases in class I antigen presentation. 
The efficiency of antigen processing and presentation from both long proteins (22) and 
minigene products (5) in vivo is governed by sequences that directly flank the epitope, and 
this has also been described for cleavage of peptides by proteasomes in vitro (5). We show 
that antigen processing by cysteine proteases is also governed by neighbouring sequences 
and that some flanking residues such as alanines determine the processing pathway to be 
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Figure 1.- Recognition of chimeric proteins with different flanking residues by pp89-
specific CTL : minigene products presentation is TAP-dependent. 
Left panel : L/Ld cells (TAP+) were infected overnight at a multiplicity of infection of 5 plaque 
forming units per cell with either rVV-HBe/N/A59pp89A5 (triangles), rVV-m17 (circles), rVV-
m19 (diamonds), or control rVV-HBe (solid line). Right panel : T2/Ld cells (TAP-) were 
infected overnight at a multiplicity of 40 with either rVV-HBe in the presence of 9pp89 
peptide used as positive control (squares) or none (solid line) as negative control, rVV-m17 
(circles) or rVV-m19 (diamonds).  
Figure 2.- Lactacystin suppresses presentation of 17mer protein but not of the related 
19mer related protein. 
L/Ld cells were infected overnight at a multiplicity of 10 in the presence of 10 PM lactacystin, 
LC, (circles) or none (triangles) with rVV-m17(panel A) or rVV-m19 (panel B). rVV-HBe 
(diamonds) was used as negative control. Lactacystin was kept throughout infection and 
51Cr-labelling until the addition of pp89-specific CTL to target cells. 
Figure 3.- Z-L3VS inhibits recognition of both 17mer and 19mer minigene products. 
L/Ld cells were infected overnight at a multiplicity of 10 in the presence of 50 PM Z-L3VS 
(circles) or none (triangles) with rVV-m17(panel A) or rVV-m19 (panel B). rVV-HBe 
(diamonds) was used as negative control. Z-L3VS was kept throughout infection and 51Cr-
labelling until the addition of CTL to target cells. 
Figure 4.- E-64 fails to block recognition of both 17mer and 19mer minigene products. 
L/Ld cells were infected overnight at a multiplicity of 10 in the presence of 100 PM E-64 
(circles) or none (triangles) with rVV-m17(panel A) or rVV-m19 (panel B). rVV-HBe 
(diamonds) was used as negative control. E-64 was kept throughout infection and 51Cr-
labelling until the addition of CTL to target cells. 




L/Ld cells were infected overnight at a multiplicity of 10 in the presence of 10 PM lactacystin, 
LC, and 50 PM E-64 (circles) or none (triangles) with rVV-m19. rVV-HBe (diamonds) was 
used as negative control. LC and E-64 were kept throughout infection and 51Cr-labelling until 
the addition of CTL to target cells. 
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